AstraZeneca Vaccine Is Effective Against COVID-19, Phase III Study Says
Early results from an Oxford-AstraZeneca trial, which involved more than 32,000 volunteers, showed two doses of the vaccine administered four weeks apart had an efficacy of 79% at preventing symptoms of COVID-19.
Early results from an Oxford-AstraZeneca trial, which involved more than 32,000 volunteers, showed two doses of the vaccine administered four weeks apart had an efficacy of 79% at preventing symptoms of COVID-19.
You received this message because you're subscribed to Breaking News Alerts emails. This email was sent by National Public Radio, Inc., 1111 North Capitol Street NE, Washington, DC 20002
No comments:
Post a Comment